Aggregation of the amyloid-b (Ab) peptide into amyloid plaques is a characteristic feature of Alzheimer's disease neuropathogenesis. We and others have previously demonstrated delayed Ab aggregation as a consequence of oxidizing a single methionine residue at position 35 (Met-35). Here, we examined the consequences of Met-35 oxidation on the extremely aggregation-prone peptides Ab1-42 and Ab1-40Arctic with respect to proto¢bril and oligomer formation as well as neurotoxicity. Size exclusion chromatography and mass spectrometry demonstrated that monomer/dimers prevailed over larger oligomers after oxidizing Met-35, and consequently proto¢bril formation and aggregation of both Ab1-42 and Ab1-40Arctic were delayed.The oxidized peptides completely lacked neurotoxic e¡ects in cortical neuronal cultures under these conditions, in contrast to the neurotoxic properties of the unoxidized peptides. We conclude that oxidation of Met-35 signi-¢cantly attenuates aggregation of Ab1-42 and Ab1-40Arctic, and thereby reduces neurotoxicity.
Introduction
Soluble amyloid-b (Ab) oligomers are currently suspected to be the major neuropathogens active in Alzheimer's disease (AD) [1, 2] . Cognitive decline has been correlated with cerebral levels of soluble Ab in AD patients [2] and neurotoxic properties have been attributed to small Ab oligomers [3] as well as larger oligomers, that is protofibrils [4] .
Whether monomeric Ab induces neurotoxicity is not unambiguous, largely because of the technical difficulties in preparing pure monomeric Ab solutions at relevant concentrations and maintaining them in a cell culture environment. For instance, the literature is conflicting on whether low molecular weight Ab (a preparation consisting largely of monomers and possibly smaller oligomers [5] ) is nontoxic [6] or toxic [4] .
We have demonstrated previously that oxidation of the single methionine residue at position 35 (Met-35) attenuates Ab1-40 trimer formation. This finding provides us with a useful tool to evaluate the neurotoxicity of low molecular weight Ab primarily consisting of monomers and dimers. Therefore, we compared the aggregation and neurotoxic properties of Ab1-42 and Ab1-40Arctic (E22G) in their reduced and oxidized form. The latter peptide is produced by carriers of the Arctic amyloid precursor protein mutation, and spontaneously generates high levels of protofibrils in vitro [1] .
Methods

b-Amyloid peptides and reagents
Synthetic Ab peptides were purchased from Biosource (Camarillo, California, USA). For the size exclusion chromatography (SEC) experiments, Ab1-42 and Ab1-40Arctic peptides were Met-35 oxidized according to our previously published protocols using 2.7% H 2 O 2 [7] . For all other experiments, oxidized AbMet-35 was purchased from Biosource where oxidation had been carried out using dimethylsulfoxide. All Met-35 oxidized and unoxidized peptides were checked for their correct identity by sequence analysis, and mass determination using mass spectrometry. All reagents and antibodies were purchased from Sigma-Aldrich (St. Louis, Missouri, USA), unless otherwise stated.
Animals
Timed-pregnant-specific pathogen-free C57Bl/6 mice were purchased from Harlan (Horst, Netherlands). All experiments were performed in accordance with international guidelines to minimize pain and discomfort (NIH-guidelines) and European Community Council Directive 86/609/EEC.
Kinetics of protofibril formation with size exclusion chromatography (SEC)
Ab1-40Arctic was dissolved in cold H 2 O, and diluted with an equal volume 2 Â phosphate-buffered saline (final concentration: 0.05 M phosphate buffer, pH 7.4, 0.10 M NaCl). Ab1-42 was dissolved in 1/10 dimethylsulfoxide before ice-cold H 2 O was added. Before SEC analysis peptide samples were incubated for different time intervals using a static kinetic incubation protocol at 301C. Samples were centrifuged at 17 900g for 5 min at 161C and the supernatant analyzed on a Merck Hitachi D-7000 HPLC LaChrom system with UV detection using a Superdex 75 PC3.2/30 column (Amersham Biosciences, Uppsala, Sweden) as described earlier [1] .
Mass spectrometry
All mass spectra were acquired using a Bruker Daltonics (Billerica, Massachusetts, USA) BioAPEX-94e superconducting 9.4 T Fourier transform ion cyclotron resonance electrospray mass spectrometer (FTICR-MS) as earlier described in Palmblad et al. [7] . Peptides were dissolved in either double distilled H 2 O or in acetonitrile: H 2 O (50 : 49) with 1% acetic acid.
Cell culture and treatment
Murine cortical neurons were isolated from day 14-16 fetal C57Bl/6 mice as described previously [8] . Dissociated neurons were plated on 100 mg/ml poly-D-lysine coated dishes at a density of about 0.25 Â 10 6 cells/cm 2 and cultured in Neurobasal (Invitrogen, San Diego, California, USA) supplemented with 2% B-27 supplement without antioxidants (Invitrogen), 0.5 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin. Neurons were fed every third day by replacing half of the medium. Neuronal cultures were exposed to Ab peptides at 7 days of culture in vitro in their own medium. Before addition to the cortical cultures Ab1-42 peptides were dissolved in the same manner as for the SEC experiments. Potential aggregates were removed using a 5 min centrifugation at 20 000 g (161C). The supernatants were used as the Ab peptide source either directly or once these had been aged at 301C for 24 h.
Neuronal toxicity
Plasma membrane integrity and nuclear morphology were assessed by double-staining cortical cultures with the nuclear dyes H-33342 (cell permeant, blue fluorescent) and SYTOX (non cell permeant, green fluorescent) and counting of neuronal condensed nuclei. About 300 cells were counted in three different fields in three different culture wells, and experiments were repeated using at least three different preparations. In addition, the percentage of viable cells was quantified by their capacity to reduce 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrasodium bromide (MTT) after incubation with 0.5 mg/ml MTT for 60 min.
Immunofluorescence
After desired period of treatment, cells were fixed in 4% paraformaldehyde. To monitor cytoskeletal alterations, we stained neurons with an anti-b-III-tubulin monoclonal antibody (1 : 300, #clone5G8; Promega, Mannheim, Germany), which recognizes only neuronal tubulin. Anti-mouse IgG antibody conjugated with Alexa Fluor 488 (Molecular Probes) was used as the secondary antibody. Nuclei were counterstained with propidium iodide.
Results
Ab oxidation delays oligomer and protofibril formation Protofibril and monomer content for Ab1-40Arctic and Ab1-42 as well as their Met-35 oxidized forms was assessed by SEC. Protofibrils are defined as the species eluting in the void volume of the column after sedimentation of fibrils and larger aggregates. The gel included peak is denoted monomer for clarity, but most likely contains some dimers and trimers as well. Monomeric levels of both unoxidized peptides disappeared rapidly while protofibrils were formed in parallel. In contrast to the unoxidized peptides, Met-35 oxidized peptides remained monomeric and produced barely detectable levels of protofibrils ( Fig. 1 ) for up to 66 h of incubation (data not shown). To determine the proportions of monomers and small oligomers, samples of both Ab1-40Arctic and Ab1-42 as well as their oxidized forms were analyzed at different time points using FTICR-MS. The two unoxidized peptides contained low amounts of monomers, dimers, trimers and tetramers which disappeared after 7-8 h, likely owing to oligomerization ( Table 1 ). The same phenomenon was observed at 100 to 1000-fold lower concentrations (1 mM and 100 mM), however with much lower signals (data not shown). In contrast, a strong monomer signal was evident for both oxidized Ab peptides for up to 8 h of incubation (Table 1) and even up to 165 h (data not shown). Some dimers, but no trimers, were detected for both oxidized peptides, indicating delayed trimer formation. Our results by SEC and FTICR-MS demonstrate that Met-35 oxidation of Ab1-40Arctic and Ab1-42 attenuates Ab oligomerization and hence protofibril formation.
Ab oxidation abolishes neurotoxicity
Making use of our finding that Met-35 oxidation attenuated the formation of Ab oligomers and protofibrils, we evaluated whether Met-35 oxidized peptides still induced neuronal death. Cortical neuronal cultures were exposed to various concentrations of unoxidized and oxidized Ab1-40Arctic and Ab1-42 either given directly or pre-aged for 24 h. Both peptide preparations (fresh or aged peptide) resulted in similar data. Ab1-40Arctic caused cell death in cortical cultures in a concentration range of 10-40 mM (Fig. 2) . Toxicity was evident after 24 h, and further increased at 48 h as measured by counting of dead neurons ( Fig. 2a ) and lost capacity to reduce MTT (Fig. 2b) . Neurons displayed classical morphological characteristics of apoptosis including shrunken nuclei with chromatin condensation and fragmentation (Fig. 3b, right panel) . Ab1-42 caused cell death of cortical neurons in a concentration range of 20-40 mM (Fig. 2) . Ab1-42 toxicity was evident after 48 h and increased at 72 h. In contrast to Ab1-40Arctic, Ab1-42 triggered pyknotic/apoptosis-like morphological characteristics including shrunken nuclei with partially condensed, but not fragmented chromatin clumps (Fig. 3b, left panel) . The oxidized peptides did not trigger any signs of cell death in the concentration range and incubation time sufficient for the deleterious effects of the unoxidized analogs (Fig. 2) .
A well-known feature of AD is cytoskeletal alterations. We therefore examined whether treatment with unoxidized and oxidized Ab would lead to a disruption of the neuronal microtubule network (Fig. 3 ). The first alterations became apparent 24-36 h after exposure to unoxidized Ab peptides and after 48-72 h the microtubule network was completely lost, leaving only small dots surrounding the nucleus ( Fig. 3a and b) . In contrast, oxidized Ab (Fig. 3a , lower panel) did not compromise the neurite network, which was indistinguishable from that of untreated cultures (Fig. 3b , middle panel).
Discussion
We have demonstrated that oxidation of a single methionine residue drastically changes the conformational fate of two aggregation-prone Ab peptides in such a way that aggregation is considerably attenuated. This has previously been observed for the much less aggregation prone wild type Ab1-40 peptide [7, 9] , and recently also for Ab1-42 [10] .
These previous observations are here extended by demonstrating both delayed oligomer and protofibril formation for Met-35 oxidized Ab1-42 as well as Ab1-40Arctic. Trimer formation seemed to be attenuated also for these highly aggregating Ab peptides, similarly to what has previously been shown for Ab1-40 [7] . Moreover, we have demonstrated that these oxidized Ab peptides completely lost their neurotoxic capacity, supposedly because of the decreased production of Ab oligomers.
It has previously been proposed that Ab Met-35 plays a critical role in neurotoxicity. Substitution of Met-35 in Ab [11] [12] [13] and studies of Ab fragments lacking Met-35 [14, 15] have demonstrated an attenuated ability for Ab to exert oxidative stress and cytotoxicity. Recent studies comparing the toxic actions of Met-35 oxidized Ab and unoxidized Ab on isolated rat brain mitochondria [16] and human neuroblastoma cells [13] showed attenuated toxicity for the oxidized form. One suggestion for the mechanism behind these observations is that the Met-35 residue plays a critical role as a mediator of oxidative stress [14] , as substitution of Met-35 [11] or studies of Ab fragments lacking Met-35 [14, 15] have shown attenuated ability to exert oxidative stress as well as neurotoxicity. Another possibility, although not thoroughly investigated, is that Met-35 oxidation prevents apoptosis, as Met-35 oxidation has been described to prevent the Ab1-42-mediated down regulation of the antiapoptotic gene bcl-2 [13] . Our findings support the view that oxidation of Met-35 renders Ab less neurotoxic by altering production of toxic Ab oligomers, oligomers that are claimed to have a range of unwanted, deleterious effects on neurons, including oxidative stress [17] and apoptosis [18] . Thus, attenuated ability of Met-35 oxidized Ab to exert oxidative stress and apoptotic events might be secondary effects to the altered aggregation behavior of this peptide.
AbMet-35 may be oxidized in AD brains through exposure to free radicals produced and released by microglia, such as superoxide, which quickly forms reactive hydrogen peroxide [19] . In concert, the association of microglia with Ab plaques is one hallmark of AD neuropathology [20] . In addition, the proportion of methionine sulfoxide could increase through decreased activity of methionine sulfoxide reductase, which reduces methionine sulfoxide back to methionine. Interestingly, Gabbita et al. (1999) have reported a decline in methionine sulfoxide reductase in brains of AD patients [21] . We propose that Ab Met-35 oxidation may constitute a means by which Ab is rendered less toxic in the brain, if oxidation of Met-35 occurs in situ to a significant extent. One may speculate how increased levels of Met-35 oxidized Ab could be beneficial in AD: (i) build-up of toxic oligomeric species may be delayed; (ii) delaying oligomerization may allow for more substantial proteolytic processing of Ab, perhaps also by the 20S proteasome [22] ; (iii) the potentially neurotoxic interaction of oxidized Ab with cellular membranes could be compromised owing to the decreased hydrophobicity of methionine sulfoxide.
Conclusion
Posttranslational modification of Met-35 to a methioninesulfoxide in aggressively aggregating Ab peptides attenuates oligomerization and reduces neurotoxicity. We propose that Ab Met-35 oxidation could be an example of an oxidative process that works in an advantageous direction to delay on-set and/or slow down progression of AD. 
